Uncertainty over the timing and amount of licensing revenue
First written in FY2023. 1 of 2 entries say "Reframed", first in FY2025. Latest entry: FY2025.
Tms moved to the "Worse" side of this theme in 2025, the same year as the typical company in this theme.
The whole theme swung hardest in 2019: 2 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2025ReframedAnnual report
「The Company’s business plan does not currently anticipate income other than milestone and royalty payments from its partner. The next milestone is expected when dosing of the fifth patient in the Phase III clinical trial of TMS-007 outside Japan is completed.」
The expected next milestone was changed from completion of dosing of the fifth patient in the U.S. TMS-007 Phase III trial to completion of dosing of the fifth patient in a Phase III trial outside Japan. - FY2023First statedAnnual report
「The Company’s business plan does not currently anticipate income other than milestone and royalty payments from Biogen. The next milestone is expected when dosing of the fifth patient in the Phase III clinical trial of TMS-007 in the United States is completed.」
The timing and amount of upfront payments, milestones and royalties may be uncertain because of licensing agreements, advancement to subsequent stages, approval, competition and patent disputes.